Table 2.

Studies of second generation drug-eluting stents and the incidence of stent thrombosis.

Study	Stent types	Followup (months)	Incidence of ST (%)
SORT OUT III [32]	ZES versus SES	18	0.5 versus 1.0
Resolute all-comers [29]	ZES versus EES	12	1.2 versus 0.3
ZEST [33]	ZES versus SES versus PES	12	0.7 versus 0 versus 0.8
ENDEAVOR IV [24]	ZES versus PES	12	0.7 versus 0.1
SPIRIT IV [21]	EES versus PES	12	0.3 versus 0.8
COMPARE [22]	EES versus PES	12	1.0 versus 3.0

SORT OUT III: Randomized Comparison of the Endeavor and the Cypher Coronary Stents in Non-Selected Angina Pectoris Patients; ZEST: Comparison of the Efficacy and the Safety of Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions; SPIRIT IV: Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Subjects with de Novo Coronary Artery Lesions; COMPARE: A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary revascularization in Daily Practice; SES: Sirolimus-Eluting stent; PES: Paclitaxel-eluting stent; ZES: Zotarolimus-eluting stent; EES: Everolimus-eluting stent.